Meera Muthukrishnan

Meera Muthukrishnan

Auto-generated profile, based on publicly available information

Meera Muthukrishnan

Department of Surgery, Division of Public Health Sciences, Washington University School of Medicine, Saint Louis, MO, USA

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2019 in Preventive Medicine Reports
Verified
Journal Article
Open access
MMMeera Muthukrishnan
Meera Muthukrishnan
LALauren D. Arnold
Lauren D. Arnold
AJAimee S. James
Aimee S. James
Colorectal cancer (CRC) is a leading cause of cancer-related death in the United States. Despite evidence that screening reduces CRC incidence and mortality, only about 60% of age-eligible adults are up-to-date on CRC screening. This analysis aims to identify self-reported barriers to CRC screening among patients in a safety-net healthcare setting. Participants were recruited from safety-net primary care sites that were participating in a trial to increase CRC screening. At baseline, patients (n = 483) completed self-report surveys that assessed demographics, healthcare and CRC screening. Barriers to CRC screening were assessed through an open-ended question. Using a basic text analysis, data were coded and organized into key topics. Overall, 65.2% ever had CRC screening; 46.4% were up-to-date. Of those who described barriers (n = 198), 22.9% said they were not due for screening or their provider had not recommended it. Other common barriers included fear or worry about the procedure or outcome, financial challenges such as lack of insurance or cost of testing, and logistic challenges such as transportation and time. Fewer said that screening was of low importance or mentioned discomfort with the procedure or colonoscopy preparation. In this safety-net setting, CRC screening rates were lower than national rates. These qualitative results are similar to quantitative findings reported in the literature but the qualitative data add to our understanding of patient-reported concerns and challenges faced by safety-net patients. These results may be applied to developing targeting communication or intervention strategies to improve CRC screening rates within safety-net health centers.

1 June 2018 in Human Vaccines & Immunotherapeutics
Verified
Journal Article
Closed access
EBEric Adjei Boakye
Eric Adjei Boakye
DLDaphne Lew
Daphne Lew
MMMeera Muthukrishnan
Meera Muthukrishnan
BTBetelihem B. Tobo
Betelihem B. Tobo
RRRebecca L. Rohde
Rebecca L. Rohde
NONosayaba Osazuwa-Peters
Nosayaba Osazuwa-Peters
Purpose: To examine correlates of HPV vaccination uptake in a nationally representative sample of 18–26-year-old adults. Methods: Young adults aged 18–26 years were identified from the 2014 and 2015 National Health Interview Survey (n = 7588). Survey-weighted multivariable logistic regression models estimated sociodemographic factors associated with HPV vaccine initiation (≥1 dose) and completion (≥3 doses). Results: Approximately 27% of study participants had initiated the HPV vaccine and 16% had completed the HPV vaccine. Participants were less likely to initiate the vaccine if they were men [(adjusted odds ratio) 0.19; (95% confidence interval) 0.16–0.23], had a high school diploma (0.40; 0.31–0.52) or less (0.46; 0.32–0.64) vs. college graduates, and were born outside the United States (0.52; 0.40–0.69). But, participants were more likely to initiate the HPV vaccine if they visited the doctor's office 1–5 times (2.09; 1.56–2.81), or ≥ 6 times (1.86; 1.48–2.34) within the last 12 months vs. no visits. Odds of completing HPV vaccine uptake followed the same pattern as initiation. And after stratifying the study population by gender and foreign-born status, these variables remained statistically significant. Conclusions: In our nationally representative study, only one out of six 18–26 year olds completed the required vaccine doses. Men, individuals with high school or less education, and those born outside the United States were less likely to initiate and complete the HPV vaccination. Our findings suggest that it may be useful to develop targeted interventions to promote HPV vaccination among those in the catch-up age range.

1 June 2018 in Contemporary Clinical Trials Communications
Verified
Journal Article
Open access
MMMeera Muthukrishnan
Meera Muthukrishnan
SSSiobhan Sutcliffe
Siobhan Sutcliffe
JHJean Hunleth
Jean Hunleth
JWJean S. Wang
Jean S. Wang
GCGraham A Colditz
Graham A Colditz
AJAimee S. James
Aimee S. James
Background: Colorectal cancer (CRC) is the second most common cancer in the US. Despite evidence that screening reduces CRC incidence and mortality, screening rates are sub-optimal with disparities by race/ethnicity, income, and geography. Rural-urban differences in CRC screening are understudied even though approximately one-fifth of the US population lives in rural areas. This focus on urban populations limits the generalizability and dissemination potential of screening interventions. Methods: Using community-based participatory research (CBPR) principles, we designed a cluster-randomized trial, adaptable to a range of settings, including rural and urban health centers. We enrolled 483 participants across 11 health centers representing 2 separate networks. Both networks serve medically-underserved communities; however one is primarily rural and one primarily urban. Results: Our goal in this analysis is to describe baseline characteristics of participants and examine setting-level differences. CBPR was a critical for recruiting networks to the trial. Patient respondents were predominately female (61.3%), African-American (66.5%), and earned<$1200 per month (87.1%). The rural network sample was older; more likely to be female, white, disabled or retired, and have a higher income, but fewer years of education. Conclusions: Variation in the samples partly reflects the CBPR process and partly reflects inherent differences in the communities. This confirmed the importance of using CBPR when planning for eventual dissemination, as it enhanced our ability to work within diverse settings. These baseline findings indicate that using a uniform approach to implementing a trial or intervention across diverse settings might not be effective or efficient.

8 April 2024 in Contemporary Clinical Trials Communications
Verified
Journal Article
Open access
CNChika Nwachukwu
Chika Nwachukwu
SMSukh Makhnoon
Sukh Makhnoon
MPMarieshia Person
Marieshia Person
MMMeera Muthukrishnan
Meera Muthukrishnan
SKSyed Kazmi
Syed Kazmi
DGDavid Gerber
David Gerber
Involving diverse populations in early-phase (phase I and II) cancer clinical trials is critical to informed therapeutic development. However, given the growing costs and complexities of early-phase trials, trial activation and enrollment barriers may be greatest for these studies at healthcare facilities that provide care to the most diverse patient groups, including those in historically underserved communities (e.g., safety-net healthcare systems). To promote diverse and equitable access to early-phase cancer clinical trials, we are implementing a novel program for the transfer of care to enhance access to early-phase cancer clinical trials. We will then perform a mixed-methods study to determine perceptions and impact of the program. Specifically, we will screen, recruit, and enroll diverse patients from an urban, integrated safety-net healthcare system to open and active early-phase clinical trials being conducted in a university-based cancer center. To evaluate this novel program, we will: (1) determine program impact and efficiency; and (2) determine stakeholder experience with and perceptions of the program. To achieve these goals, we will conduct preliminary cost analyses of the program. We will also conduct surveys and interviews with patients and caregivers to elucidate program impact, challenges, and areas for improvement. We hypothesize that broadening access to early-phase cancer trials conducted at experienced centers may improve equity and diversity. In turn, such efforts may enhance the efficiency and generalizability of cancer clinical research.

4 October 2025 in Patient Education and Counseling
Verified
Journal Article
Closed access
JTJasmin A. Tiro
Jasmin A. Tiro
SMSadie Metcalfe
Sadie Metcalfe
MMMeera Muthukrishnan
Meera Muthukrishnan
AJAngelina Jose
Angelina Jose
KHKris Hansen
Kris Hansen
RWRachel L. Winer
Rachel L. Winer